ABCL

Abcellera Biologics Inc

Add to Watchlist

Advanced Chart

5.110

+0.09(1.793%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.150

Open

5.010

VWAP

4.95

Vol

5.19M

Mkt Cap

1.53B

Low

4.670

Amount

25.69M

EV/EBITDA(TTM)

Total Shares

294.05M

919.99M

EV/OCF(TTM)

P/S(TTM)

65.34

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

8.00M

+56.93%

-0.162

+34.73%

7.83M

+20.26%

-0.160

-5.88%

7.70M

+5.11%

-0.160

+23.08%

Estimates Revision

The market is revising Downward the revenue expectations for AbCellera Biologics Inc. (ABCL) for FY2025, with the revenue forecasts being adjusted by -20.69% over the past three months. During the same period, the stock price has changed by 97.30%.

Revenue Estimates for FY2025

Revise Downward

-20.69%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.26%

In Past 3 Month

Stock Price

Go Up

+97.30%

In Past 3 Month

5 Analyst Rating

36.99% Upside

Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

36.99% Upside

Current: 5.110

Low

5.00

Averages

7.00

High

10.00

36.99% Upside

Current: 5.110

Low

5.00

Averages

7.00

High

10.00

Leerink

Outperform

initiated

2025-07-07

Reason

Leerink

Price Target

2025-07-07

initiated

Outperform

Reason

Leerink assumed coverage of AbCellera with an Outperform rating and $5 price target. The firm likes AbCellera's pivot from being an antibody discovery platform company to developing their own internal pipeline, and it sees potential for ABCL575 in atopic dermatitis and ABCL635 in vasomotor symptoms. Both programs are up-and-coming agents with validated mechanisms in large commercial opportunities.

Truist

Buy

downgrade

$28 -> $10

2025-05-16

Reason

Truist

Price Target

$28 -> $10

2025-05-16

downgrade

Buy

Reason

Truist lowered the firm's price target on AbCellera to $10 from $28 and keeps a Buy rating on the shares. The firm has updated its model after the company's Q1 results, though it continues to be positive about AbCellera, highlighting its continued execution of their wholly owned clinical pipeline, and given the company's hybrid business model with a focus shifting towards a clinical stage biotech, Truist is also updating its discount rate to reflect the transition, the analyst tells investors in a research note.

Stifel

Stephen Willey

Buy

downgrade

$10 -> $8

2025-05-09

Reason

Stifel

Stephen Willey

Price Target

$10 -> $8

2025-05-09

downgrade

Buy

Reason

Keybanc

Scott Schoenhaus

Buy

Maintains

$4 → $5

2025-04-16

Reason

Keybanc

Scott Schoenhaus

Price Target

$4 → $5

2025-04-16

Maintains

Buy

Reason

KeyBanc raised the firm's price target on AbCellera to $5 from $4 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on legislative policies, healthcare system utilization, and macro concerns on a slowing economy paired with potentially higher inflation. While valuations in HCIT land remain discounted vs. healthcare more broadly, KeyBanc thinks investors should be focused on companies that can drive meet/beats over the next 12 months. Specifically, it sees the least risk from a revenue and earnings perspective from companies that are well positioned in the more stable healthcare end markets serving the payers and large pharma.

Benchmark

Robert Wasserman

Hold

Reiterates

n/a

2025-03-03

Reason

Benchmark

Robert Wasserman

Price Target

n/a

2025-03-03

Reiterates

Hold

Reason

Stifel

Stephen Willey

Strong Buy

Maintains

$12 → $10

2025-02-28

Reason

Stifel

Stephen Willey

Price Target

$12 → $10

2025-02-28

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Abcellera Biologics Inc (ABCL.O) is -8.42, compared to its 5-year average forward P/E of 12.19. For a more detailed relative valuation and DCF analysis to assess Abcellera Biologics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

12.19

Current PE

-8.42

Overvalued PE

59.52

Undervalued PE

-35.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

8.68

Current EV/EBITDA

-4.65

Overvalued EV/EBITDA

67.28

Undervalued EV/EBITDA

-49.91

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

30.57

Current PS

34.49

Overvalued PS

47.49

Undervalued PS

13.65

Financials

Annual

Quarterly

FY2025Q1

YoY :

-57.45%

4.24M

Total Revenue

FY2025Q1

YoY :

+14.15%

-62.66M

Operating Profit

FY2025Q1

YoY :

+12.34%

-45.62M

Net Income after Tax

FY2025Q1

YoY :

+7.14%

-0.15

EPS - Diluted

FY2025Q1

YoY :

-66.30%

-22.19M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+73.08%

-619.94

FCF Margin - %

FY2025Q1

YoY :

+164.04%

-1.08K

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ABCL News & Events

Events Timeline

2025-05-30 (ET)

2025-05-30

13:01:34

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial

2025-05-14 (ET)

2025-05-14

17:01:58

AbCellera receives NOL from Health Canada for ABCL635 clinical trial application

2025-05-12 (ET)

2025-05-12

15:50:44

AbCellera says Federal Circuit rejects Bruker Cellular's invalidity challenge

News

2.0

07-21Benzinga

Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday

9.0

06-02NASDAQ.COM

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

4.0

05-16Benzinga

Truist Securities Maintains Buy on AbCellera Biologics, Lowers Price Target to $10

People Also Watch

UVSP

Univest Financial Corp

indie Semiconductor Inc

Murano Global Investments Plc

Algoma Steel Group Inc

CBL & Associates Properties Inc

Atlanticus Holdings Corp

FAQ

What is Abcellera Biologics Inc (ABCL) stock price today?

The current price of ABCL is 5.11 USD — it has increased 1.79 % in the last trading day.

ABCL

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ABCL News & Events

Events Timeline

News

People Also Watch

FAQ

What is Abcellera Biologics Inc (ABCL) stock price today?

What is Abcellera Biologics Inc (ABCL)'s business?

What is the price predicton of ABCL Stock?

What is Abcellera Biologics Inc (ABCL)'s revenue for the last quarter?

What is Abcellera Biologics Inc (ABCL)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Abcellera Biologics Inc (ABCL)'s fundamentals?

How many employees does Abcellera Biologics Inc (ABCL). have?

What is Abcellera Biologics Inc (ABCL) market cap?